Batiraxcept has "Best in Class Potential" - H.C. Wainwright Reiterates Buy Rating on Aravive (ARAV) with $26 Price Target

Go back to Batiraxcept has "Best in Class Potential" - H.C. Wainwright Reiterates Buy Rating on Aravive (ARAV) with $26 Price Target
(NASDAQ: ARAV) Delayed: 0.04 --0 (-0%)
Previous Close $0.04    52 Week High
Open $0.01    52 Week Low
Day High $0.04    P/E N/A 
Day Low $0.04    EPS
Volume 148